CVS CVS HEALTH CORPORATION
XNYS
94.48
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
CVS
$94.48
—
Key stats
$94.48
- 52-Week Range
- $69.51 – $110.68
- YTD
- +17.91%
- IV Rank (30D)
- 75.73
- Straddle Price
- $8.03
- P/C Vol Ratio
- 0.15
- Market Cap
- $119.5B
- Open
- $93.08
- Day Range
- $92.49 – $94.83
- Volume
- 7,227,265
- Prev Close
- $93.45
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.15% |
| Beta vs SPY | 0.65 |
| Cost of Equity (CAPM) | 8.42% (VRP-adj) |
| WACC | 7.51% |
| Volatility Risk Premium | +31.1pp (IV − HV30) |
| Effective Tax Rate | 15.6% |
| Rev. Growth (YoY, DCF input) | +3.1% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $11.8B |
| Return on Equity (TTM) | 6.1% |
| Book / Price | 67.0% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 13.6% |
| FCF Margin (TTM) | 2.8% |
| Debt / Equity | 0.74 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| Market-Implied Growth | -5.4% (reverse-DCF on current price) |
| SMA 50 | $91.65 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $88.67 |
| Bollinger Width / SMA20 | 14.7% (drives anchor stability) |
| Net Debt | $48.1B |
| Market Cap | $119B |
Peers used for multiples: ELV, UNH, XOM
(filtered from 8 ETF-co-members; sector bias active)
60-Day Conviction
49%
20-Day Fair Value
≈ by Nov 20, 2026
$95.29
α +0.9%
rank 23%
conviction
53%
40-Day Fair Value
≈ by Dec 21, 2026
$95.99
α +1.6%
rank 13%
conviction
51%
60-Day Fair Value
≈ by Jan 19, 2027
$95.80
α +1.4%
rank 10%
conviction
49%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $156.35 | 18% | |
| DDM (Gordon) | $65.00 | 14% | |
| Peer P/E | $90.93 | 5% | median 23.2× · 3 peers |
| Peer EV/EBITDA | $133.83 | 5% | median 13.2× · 3 peers |
| Peer P/B | $144.59 | 5% | median 2.3× · 3 peers |
| Peer P/S | $280.08 | 5% | median 0.8× · 3 peers |
| Market Anchor (SMA50) | $91.65 | 28% | stability 76% (BB-width) |
| Options Expected (B-L 30d) | $93.71 | 18% | 58 strikes · skew -0.09 |
As of 2026-10-22 · updated
Related
About
- Industry (SIC)
- RETAIL-DRUG STORES AND PROPRIETARY STORES (5912) · industry map
- Exchange
- XNYS
- Market Cap
- $119.5B
- Employees
- 300,000
- List Date
- 1952-10-01
- CIK
- 0000064803
- Next Earnings
- 2026-11-04 (Pre-Market)
- EPS Forecast
- $1.62 (9 est.)
- Headquarters
- Woonsocket, RI
- Homepage
- https://www.cvshealth.com
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates around 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It operates a top-tier health insurer (acquired through Aetna) through which it serves about 26 million medical members. The acquisition of Oak Street Health added primary care services to the mix, which could have significant synergies with all existing business lines.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 2.37% | 2.26% | -5.05% | -8.01% | 27.73% | -7.00% | 2.05% |
| Feb | -4.66% | -2.47% | -4.51% | 0.61% | 17.46% | 5.94% | 2.06% |
| Mar | 8.59% | -0.82% | -9.89% | 8.02% | 4.39% | -12.05% | -0.29% |
| Apr | 2.83% | -4.91% | -3.65% | -14.89% | -1.87% | 14.90% | -1.26% |
| May | 11.26% | 0.26% | -7.93% | 5.84% | -7.79% | 10.83% | 2.08% |
| Jun | -2.83% | -4.02% | 0.36% | -1.91% | 8.46% | 14.16% | 2.37% |
| Jul | 0.17% | 1.85% | 7.05% | 3.75% | -10.75% | -0.22% | 0.31% |
| Aug | 4.83% | 2.22% | -11.87% | -4.65% | 17.10% | -10.88% | -0.54% |
| Sep | -0.99% | -4.56% | 6.32% | 9.59% | 1.75% | -12.20% | -0.01% |
| Oct | 6.20% | -3.13% | -0.98% | -8.25% | 1.67% | 10.89%* | 1.07% |
| Nov | -1.75% | 7.67% | -1.13% | 7.24% | 2.45% | -- | 2.90% |
| Dec | 16.20% | -8.32% | 15.30% | -24.02% | 0.33% | -- | -0.10% |
| Total | 48.52% | -14.00% | -17.64% | -28.40% | 70.82% | 9.06% | 11.39% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $89.14
SMA 50: $91.64
SMA 200: $88.45
Current: $94.48
EMA 12: $91.50
EMA 26: $90.80
MACD: 0.6943 | Signal: 1.0836
BEARISH
ADX (14): 24.05
WEAK TREND
+DI: 28.78
−DI: 21.18
Momentum Oscillators
RSI (14): 61.60
NEUTRAL
Stoch %K: 90.82
Stoch %D: 91.79
Williams %R: -8.01
Volume & Volatility
BB Upper: $95.20
BB Lower: $83.08
NEUTRAL
OBV: 318,059,029
Vol SMA 20: 9,293,791
Vol ROC: -8.57%
ATR: $2.23
True Range: $2.34
HV 20: 28.0%
HV 30: 27.4%
HV 60: 27.3%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-24T00:00:00 – 2026-10-22T00:00:00
AI Analysis
Here is the LLM Stock Analysis Report for CVS:
Executive Summary
Overall assessment: NEUTRAL with confidence level (7/10) Key drivers and primary risks: * Technical indicators suggest a consolidating trend, with momentum oscillators indicating neutral sentiment. * Recent news headlines are generally positive, but volatility metrics show low risk. * Risk management considerations include support levels and position sizing considerations.
Recent news sentiment impact: Positive news from the healthcare services market size and Autonomize's leadership team strengthening could contribute to CVS' growth potential.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): Neutral, Medium-term (1-3 months): Consolidating trend, Long-term (3-12 months): Uptrend
Support/Resistance Levels: Key price levels: + Lower: $96.26 (Bollinger Band lower) + Middle: $104.81 (SMA 50 and current price) + Upper: $113.36 (Bollinger Band upper)
Momentum Signals: * RSI interpretation: Neutral (32.12) - not overbought or oversold * MACD signal: Bullish (Histogram = 0.33) - momentum supports the uptrend * Bollinger Bands position: Oversold (-86.38%) - a potential buy signal
Volume Analysis: Volume trends and institutional interest signals: + SMA 20: 7536872.70 + On-Balance Volume (OBV): 449122535.54 + Volume Rate of Change: -96.81% - indicates low volume and potential consolidation
News & Sentiment Analysis
Recent Headlines Summary: Key themes: * Positive news from the healthcare services market size and Autonomize's leadership team strengthening. * Neutral headlines from Fluency and UnitedHealth.
Sentiment Assessment: Aggregate news sentiment: POSITIVE (4 positive headlines, 2 neutral)
Catalyst Identification: Upcoming events: + No earnings data available + IV Rank suggests low volatility - stock moves less than market
Market Narrative: News aligns with the consolidating trend and technical signals.
Risk & Volatility Assessment
Beta Interpretation: Risk relative to market: 0.15 (vs SPY) - low risk
Volatility Regime: Current vs historical volatility levels: + Stock Volatility: 0.31 - indicates relatively stable price movement + IV Rank: 11.1% (Low) - shows if volatility is historically high/low
Options Market Signals: IV rank, put/call ratios, unusual activity: * IV Rank: 11.1% (Low) * Current IV: 36.8% * Expected Move: $6.00 (31 DTE), 7-DTE: $3.80 * Volume Flow: 197 calls vs 210 puts + Open Interest: 288 calls vs 216 puts
Downside Protection: Support levels and risk management considerations: * Lower: $96.26 (Bollinger Band lower) * Middle: $104.81 (SMA 50 and current price)
Market Context & Positioning
Sector Performance: Relative strength vs sector/market: + Healthcare Services - CVS is positioned above the sector's average
Institutional Activity: Volume patterns suggesting institutional interest: + SMA 20: 7536872.70 - suggests stable volume
Correlation Analysis: How stock moves relative to market (R-squared interpretation): + Correlation: 0.06 - CVS is relatively independent of the broader market's movements
Relative Valuation: Position within trading range: + Lower: $96.26 (Bollinger Band lower) + Middle: $104.81 (SMA 50 and current price)
Key Levels & Action Items
Critical Price Levels: * Support: $96.26 (Bollinger Band lower), $104.81 (SMA 50 and current price) * Resistance: $113.36 (Bollinger Band upper)
Breakout/Breakdown Levels: Technical levels that could trigger significant moves: + Breakout above $113.36 (Bollinger Band upper) or breakdown below $96.26 (Bollinger Band lower)
Time-Sensitive Catalysts: Earnings dates, FDA approvals, product launches: * No earnings data available
Risk Management: Stop-loss levels and position sizing considerations: * Lower: $96.26 (Bollinger Band lower) * Middle: $104.81 (SMA 50 and current price)
Please note that this report is based on the provided data, and actual market conditions may differ.
Generated
News
All CVS news →
Plus: CVS health unit resolves illegal opioid prescription claims and drones struck two commercial ships sailing near NATO waters
Humana and Clover soared after their Medicare Advantage plans earned higher Star Ratings. CVS Health and Alignment Healthcare tanked on Friday after their plans got downgraded. The post Humana, Clover Soar On Medicare Advantage Star Rating; These Stocks Sink appeared first on…
Earnings History
14 of 22 under expected move
Avg Expected Move
5.10%
Avg Actual Move
4.62%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-05-04 | Pre-Market | 3.58% | 4.41% | 1.23x | Exceeded |
| 2021-08-04 | Pre-Market | 3.44% | 2.92% | 0.85x | Within |
| 2021-11-03 | Pre-Market | 4.07% | 5.69% | 1.40x | Exceeded |
| 2022-01-11 | Pre-Market | 2.26% | 0.93% | 0.41x | Within |
| 2022-05-04 | Pre-Market | 4.32% | 4.78% | 1.11x | Exceeded |
| 2022-08-03 | Pre-Market | 4.32% | 6.30% | 1.46x | Exceeded |
| 2022-11-02 | Pre-Market | 4.52% | 2.30% | 0.51x | Within |
| 2023-01-09 | Pre-Market | 2.69% | 0.12% | 0.04x | Within |
| 2023-05-03 | Pre-Market | 4.52% | 3.68% | 0.81x | Within |
| 2023-08-02 | Pre-Market | 4.75% | 3.33% | 0.70x | Within |
| 2023-11-01 | Pre-Market | 4.88% | 0.41% | 0.08x | Within |
| 2024-01-05 | Pre-Market | 1.52% | 1.13% | 0.74x | Within |
| 2024-05-01 | Pre-Market | 4.84% | 16.84% | 3.48x | Exceeded |
| 2024-08-07 | Pre-Market | 8.37% | 3.21% | 0.38x | Within |
| 2024-11-06 | Pre-Market | 8.05% | 11.33% | 1.41x | Exceeded |
| 2025-02-12 | Pre-Market | 8.26% | 14.95% | 1.81x | Exceeded |
| 2025-05-01 | Pre-Market | 6.53% | 4.11% | 0.63x | Within |
| 2025-07-31 | Pre-Market | 7.68% | 0.32% | 0.04x | Within |
| 2025-10-29 | Pre-Market | 5.35% | 1.95% | 0.36x | Within |
| 2026-02-10 | Pre-Market | 6.35% | 0.09% | 0.01x | Within |
| 2026-05-06 | Pre-Market | 5.99% | 7.65% | 1.28x | Exceeded |
| 2026-08-05 | Pre-Market | 5.94% | 5.08% | 0.86x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
CVS Options Activity & IV Rank
CVS IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 37.2%
7-DTE IV: 29.8%
Expected Move: $8.03
7-DTE Move: $3.43
Days to Exp: 29 (2026-11-20)
Options Flow
Call Volume: 1,802
Put Volume: 274
P/C Volume: 0.152
BULLISH
Call OI: 22,657
Put OI: 24,453
P/C OI: 1.079
Total OI: 47,110
ATM Options Pricing
ATM Call: $4.40
ATM Put: $3.62
Call %: 4.7%
Put %: 3.8%
Chain Summary
Chain Volume: 43,296
Chain OI: 303,838
Last Updated: 10/22/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 84th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
84%
vs own history
GEX tilt
+0.46
OI-weighted, today
Vanna tilt
+0.40
δ-sensitivity to IV
Charm tilt
-0.35
δ-decay vs time
Vanna tilt +0.40: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.35: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 206 ATM contracts, 107k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
84%
+10.0
pts
EXTREME
as of Oct 22 · ATM 45.3% / Wing 55.3%
30 DTE / 10d
23%
+2.3
pts
EXTREME
as of Oct 22 · ATM 37.8% / Wing 40.2%
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)18.3LowOct 22
IV Rank (30 DTE)75.7HighOct 22
Straddle Price (30 DTE)$8.03Oct 22
Beta Analysis
Risk Metrics
Beta: 0.1596
Alpha: 16.96%
Correlation: 0.0646
R-Squared: 0.4%
Stock Volatility: 31.5%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
CVS Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 1,276,500,000 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
57 filers$2.12B notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $409.80M | 19.30% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $299.59M | 14.11% | 2026-06-30 |
| 3 | UBS Group AG Custodian | $221.53M | 10.44% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $190.31M | 8.96% | 2026-06-30 |
| 5 | Goldman Sachs Group Inc Custodian | $173.72M | 8.18% | 2026-06-30 |
| 6 | Walleye Trading LLC | $98.69M | 4.65% | 2026-06-30 |
| 7 | IMC-Chicago, LLC Custodian | $94.06M | 4.43% | 2026-06-30 |
| 8 | MASTERS CAPITAL MANAGEMENT LLC | $51.73M | 2.44% | 2026-06-30 |
| 9 | TORONTO DOMINION BANK | $51.73M | 2.44% | 2026-06-30 |
| 10 | Long Focus Capital Management, LLC | $50.71M | 2.39% | 2026-06-30 |
| 11 | Wolverine Trading, LLC Custodian | $50.30M | 2.37% | 2025-09-30 |
| 12 | Simplex Trading, LLC Custodian | $42.06M | 1.98% | 2026-06-30 |
| 13 | Royal Bank of Canada Custodian | $41.41M | 1.95% | 2026-06-30 |
| 14 | JPMorgan Chase & Co Custodian | $26.41M | 1.24% | 2026-06-30 |
| 15 | Alphadyne Asset Management LP | $23.75M | 1.12% | 2026-06-30 |
| 16 | Caption Management, LLC | $22.31M | 1.05% | 2026-06-30 |
| 17 | GROUP ONE TRADING LLC Custodian | $21.64M | 1.02% | 2026-06-30 |
| 18 | TUDOR INVESTMENT CORP ET AL | $20.60M | 0.97% | 2026-06-30 |
| 19 | Cubist Systematic Strategies, LLC | $19.19M | 0.90% | 2025-09-30 |
| 20 | Balyasny Asset Management L.P. | $18.92M | 0.89% | 2026-06-30 |
| 21 | Squarepoint Ops LLC | $18.20M | 0.86% | 2026-06-30 |
| 22 | Twin Tree Management, LP | $16.35M | 0.77% | 2026-06-30 |
| 23 | Eisler Capital Management Ltd. | $15.59M | 0.73% | 2025-09-30 |
| 24 | Qube Research & Technologies Ltd | $14.99M | 0.71% | 2026-06-30 |
| 25 | D. E. Shaw & Co., Inc. Custodian | $12.86M | 0.61% | 2026-06-30 |
57 filers$1.66B notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $267.08M | 16.10% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $252.32M | 15.21% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $231.06M | 13.92% | 2026-06-30 |
| 4 | Walleye Trading LLC | $98.05M | 5.91% | 2026-06-30 |
| 5 | Goldman Sachs Group Inc Custodian | $94.37M | 5.69% | 2026-06-30 |
| 6 | D. E. Shaw & Co., Inc. Custodian | $77.78M | 4.69% | 2026-06-30 |
| 7 | IMC-Chicago, LLC Custodian | $73.89M | 4.45% | 2026-06-30 |
| 8 | Eisler Capital Management Ltd. | $45.57M | 2.75% | 2025-09-30 |
| 9 | Wolverine Trading, LLC Custodian | $44.55M | 2.68% | 2025-09-30 |
| 10 | Centiva Capital, LP | $35.68M | 2.15% | 2026-06-30 |
| 11 | GROUP ONE TRADING LLC Custodian | $31.86M | 1.92% | 2026-06-30 |
| 12 | Alphadyne Asset Management LP | $31.82M | 1.92% | 2026-06-30 |
| 13 | UBS Group AG Custodian | $30.66M | 1.85% | 2026-06-30 |
| 14 | Squarepoint Ops LLC | $29.42M | 1.77% | 2026-06-30 |
| 15 | Simplex Trading, LLC Custodian | $29.00M | 1.75% | 2026-06-30 |
| 16 | BNP Paribas Financial Markets Custodian | $26.69M | 1.61% | 2026-06-30 |
| 17 | JPMorgan Chase & Co Custodian | $23.31M | 1.40% | 2026-06-30 |
| 18 | Cubist Systematic Strategies, LLC | $22.41M | 1.35% | 2025-09-30 |
| 19 | CREDIT AGRICOLE S A | $19.66M | 1.18% | 2026-06-30 |
| 20 | Qube Research & Technologies Ltd | $17.94M | 1.08% | 2026-06-30 |
| 21 | CAPSTONE INVESTMENT ADVISORS, LLC | $17.77M | 1.07% | 2026-06-30 |
| 22 | Millennium Management LLC Custodian | $16.91M | 1.02% | 2026-06-30 |
| 23 | Barclays PLC Custodian | $14.72M | 0.89% | 2026-06-30 |
| 24 | Balyasny Asset Management L.P. | $13.71M | 0.83% | 2026-06-30 |
| 25 | TUDOR INVESTMENT CORP ET AL | $13.20M | 0.80% | 2026-06-30 |
CVS Insider Trading (Form 4)
Latest: 2026-06-29Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-06-29 | James David Clark | SVP, Cont & Chief Acct Officer | Tax (F) | −454 | $90.98 | -$41.3K | EDGAR |
| 2026-06-01 | Amy Compton-Phillips | EVP, Chief Medical Officer | Tax (F) | −7,618 | $90.98 | -$693.1K | EDGAR |
| 2026-06-01 | Brian Newman | EVP, Chief Financial Officer | Tax (F) | −2,478 | $90.98 | -$225.4K | EDGAR |
| 2026-05-22 | Fernando Aguirre | Director | Disp (D) | −32,000 | $93.76 | -$3.00M | EDGAR |
| 2026-05-21 | Larry Robbins | Director | Sell (S) | −3,372,000 | $94.15 | -$317.47M | EDGAR |
| 2026-05-15 | Larry Robbins | Director | Grant (A) | +1,930 RSU | — | EDGAR | |
| 2026-05-15 | Douglas H. Shulman | Director | Grant (A) | +1,447 RSU | — | EDGAR | |
| 2026-05-15 | C David Brown II | Director | Award (A) | +1,544 | $97.15 | $150.0K | EDGAR |
| 2026-05-15 | Anne A. Finucane | Director | Grant (A) | +1,544 RSU | — | EDGAR | |
| 2026-05-15 | Alecia A Decoudreaux | Director | Grant (A) | +1,447 RSU | — | EDGAR | |
| 2026-05-15 | Guy P Sansone | Director | Award (A) | +1,447 | $97.15 | $140.6K | EDGAR |
| 2026-05-15 | Leslie V Norwalk | Director | Award (A) | +1,447 | $97.15 | $140.6K | EDGAR |
| 2026-05-15 | J Scott Kirby | Director | Award (A) | +1,447 | $97.15 | $140.6K | EDGAR |
| 2026-05-15 | Jeffrey R. Balser | Director | Award (A) | +2,058 | $97.15 | $199.9K | EDGAR |
| 2026-05-15 | Fernando Aguirre | Director | Award (A) | +1,563 | $97.15 | $151.8K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
CVS Insider Holdings
26 insiders · @ $94.48
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Larry Robbins | Director | 5,195,261 | $490.85M | -$571.17M | 6 | 2026-05-21 |
| 2 | J. David Joyner | President, CEO and Chair | 160,860 | $15.20M | -$29.36M | 34 | 2026-04-02 |
| 3 | C David Brown II | Director | 129,316 | $12.22M | -$16.35M | 58 | 2026-05-15 |
| 4 | Jean Pierre Millon | Director | 112,217 | $10.60M | -$4.39M | 48 | 2024-11-25 |
| 5 | Heidi B Capozzi | EVP and Chief People Officer | 84,490 | $7.98M | $4.6K | 5 | 2026-04-02 |
| 6 | Prem S Shah | EVP and Group President | 62,852 | $5.94M | -$5.10M | 22 | 2026-04-02 |
| 7 | Steven H Nelson | EVP and President, Aetna | 43,630 | $4.12M | $1.3K | 4 | 2026-04-02 |
| 8 | Thomas F. Cowhey | EVP and CFO | 41,109 | $3.88M | $0 | 5 | 2025-04-03 |
| 9 | Samrat S. Khichi | EVP, CPO and General Counsel | 38,139 | $3.60M | $0 | 8 | 2026-04-02 |
| 10 | Nancy Ann Deparle | Director | 34,169 | $3.23M | $0 | 23 | 2024-11-25 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
CVS Board & Officers
As of SEC filings through Jun 29, 2026Directors 14
- C David Brown II · since Mar 22, 2007
- Anne A. Finucane · since Jan 20, 2011
- Alecia A Decoudreaux · since Mar 5, 2015
- Fernando Aguirre · since Nov 28, 2018
- Roger N Farah · since Nov 28, 2018
- Jeffrey R. Balser · since Sep 12, 2022
- J Scott Kirby · since Oct 1, 2023
- Michael F Mahoney · since Nov 1, 2023
- Douglas H. Shulman · since Nov 17, 2024
- Guy P Sansone · since Nov 17, 2024
- Larry Robbins · since Nov 17, 2024
- Leslie V Norwalk · since Nov 17, 2024
- J. David Joyner · listed since Dec 2024
- John E Gallina · since Mar 19, 2026
Officers 9
- J. David Joyner · President and CEO · listed since Dec 2024
- Steven H Nelson · EVP and President, Aetna · since Nov 6, 2024
- Prem S Shah · EVP and Group President · listed since Dec 2024
- Brian Newman · EVP, Chief Financial Officer · since May 12, 2025
- James David Clark · SVP, Cont & Chief Acct Officer · since Nov 19, 2018
- Heidi B Capozzi · EVP and Chief People Officer · since Sep 9, 2024
- Amy Compton-Phillips · EVP, Chief Medical Officer · since May 19, 2025
- Tilak Mandadi · EVP, Chief Exp & Tech Officer · listed since Sep 2025
- Samrat S. Khichi · EVP, CPO and General Counsel · since Feb 13, 2023
Changes in the last 10 years (70)
| Mar 19, 2026 | John E Gallina became a director |
| Sep 2, 2025 | Tilak Mandadi listed as EVP, Chief Exp & Tech Officer (previously EVP, Chief Technology Officer) in SEC filings |
| May 19, 2025 | Amy Compton-Phillips became EVP, Chief Medical Officer |
| May 12, 2025 | Brian Newman became EVP, Chief Financial Officer |
| Apr 7, 2025 | The company announced the departure of Thomas F. Cowhey as EVP and CFO in an SEC filing |
| Dec 26, 2024 | J. David Joyner first listed as a director in an SEC filing |
| Dec 3, 2024 | Prem S Shah listed as EVP and Group President (previously EVP and Pres-Pharm, Consumer W) in SEC filings |
| Dec 3, 2024 | J. David Joyner listed as President and CEO (previously EVP&President-PharmacyServices) in SEC filings |
| Nov 17, 2024 | Leslie V Norwalk became a director |
| Nov 17, 2024 | Larry Robbins became a director |
| Nov 17, 2024 | Guy P Sansone became a director |
| Nov 17, 2024 | Douglas H. Shulman became a director |
| Nov 6, 2024 | Steven H Nelson became EVP and President, Aetna |
| Oct 17, 2024 | The company announced the departure of Karen S Lynch from the board in an SEC filing |
| Oct 17, 2024 | The company announced the departure of Karen S Lynch as President and CEO in an SEC filing |
| Sep 9, 2024 | Heidi B Capozzi became EVP and Chief People Officer |
| Apr 3, 2024 | Thomas F. Cowhey listed as EVP and CFO (previously SVP, Interim CFO) in SEC filings |
| Feb 14, 2024 | Prem S Shah listed as EVP and Pres-Pharm, Consumer W (previously EVP and Co-President of Retail) in SEC filings |
| Jan 5, 2024 | The company announced the departure of Shawn M Guertin as EVP & Chief Financial Officer in an SEC filing |
| Nov 1, 2023 | Michael F Mahoney became a director |
| Oct 13, 2023 | Thomas F. Cowhey became SVP, Interim CFO |
| Oct 1, 2023 | J Scott Kirby became a director |
| Sep 1, 2023 | Brian A Kane became EVP/President, Aetna |
| Feb 13, 2023 | Samrat S. Khichi became EVP, CPO and General Counsel |
| Feb 3, 2023 | J. David Joyner first listed as EVP&President-PharmacyServices in an SEC filing |
| Jan 18, 2023 | The company announced the departure of Alan Lotvin as EVP&President-PharmacyServices in an SEC filing |
| Sep 12, 2022 | Jeffrey R. Balser became a director |
| Jul 25, 2022 | Tilak Mandadi became EVP, Chief Technology Officer |
| May 13, 2022 | David W Dorman reported in an SEC filing no longer being a director |
| May 11, 2022 | Sreekanth K Chaguturu became EVP and Chief Medical Officer |
| Mar 21, 2022 | The company announced the departure of Jonathan C Roberts as EVP & Chief Operating Officer in an SEC filing |
| Mar 8, 2022 | The company announced the departure of Tony L White from the board in an SEC filing |
| Jan 1, 2022 | Prem S Shah became EVP and Co-President of Retail |
| Jan 1, 2022 | Michelle A Peluso became EVP and Co-President of Retail |
| Dec 1, 2021 | Karen S Lynch listed as President and CEO (previously EVP and President, Aetna) in SEC filings |
| Dec 1, 2021 | Karen S Lynch first listed as a director in an SEC filing |
| Jun 2, 2021 | Larry J Merlo reported in an SEC filing no longer being a director |
| May 28, 2021 | Shawn M Guertin became EVP & Chief Financial Officer |
| Apr 2, 2021 | Lisa Bisaccia reported in an SEC filing no longer being EVP and Chief HR Officer |
| Apr 2, 2021 | Alan Lotvin listed as EVP&President-PharmacyServices (previously EVP and President-CVS Caremark) in SEC filings |
| Mar 29, 2021 | Larry J Merlo no longer listed as President and CEO in SEC filings |
| Mar 2, 2021 | Joshua Matthew Flum reported in an SEC filing no longer being EVP, Ent Strategy & Digital |
| Feb 8, 2021 | Laurie P. Havanec became EVP and Chief People Officer |
| Feb 1, 2021 | Daniel P Finke became EVP/Pres, Health Care Benefits |
| Dec 4, 2020 | Karen S Lynch listed as EVP and President, Aetna (previously EVP & Pres, Aetna Bus Unit) in SEC filings |
| Nov 30, 2020 | Neela Montgomery became EVP and Pres., Pharmacy/Retail |
| May 28, 2020 | Jonathan E. Mayhew listed as EVP - Transformation (previously EVP, Chief Transformation Off) in SEC filings |
| May 13, 2020 | Alan Lotvin listed as EVP and President-CVS Caremark (previously EVP, Transformation) in SEC filings |
| Mar 11, 2020 | Jonathan E. Mayhew became EVP, Chief Transformation Off |
| Mar 3, 2020 | Derica W Rice reported in an SEC filing no longer being EVP & President, CVS Caremark |
| Apr 12, 2019 | Joshua Matthew Flum listed as EVP, Ent Strategy & Digital (previously EVP, Corp Strategy & Bus Dev) in SEC filings |
| Mar 1, 2019 | Eva C Boratto listed as EVP & CFO (previously EVP, Cont & Chief Acct Officer) in SEC filings |
| Nov 30, 2018 | David M Denton reported in an SEC filing no longer being EVP, CFO |
| Nov 28, 2018 | Roger N Farah became a director |
| Nov 28, 2018 | Mark T Bertolini became a director |
| Nov 28, 2018 | Karen S Lynch became EVP & Pres, Aetna Bus Unit |
| Nov 28, 2018 | Joshua Matthew Flum became EVP, Corp Strategy & Bus Dev |
| Nov 28, 2018 | Fernando Aguirre became a director |
| Nov 28, 2018 | Edward J Ludwig became a director |
| Nov 19, 2018 | James David Clark became SVP, Cont & Chief Acct Officer |
| Jun 4, 2018 | Kevin Hourican became EVP & President, CVS Pharmacy |
| Jun 4, 2018 | Derica W Rice became EVP & President, CVS Caremark |
| Jun 4, 2018 | Alan Lotvin became EVP, Transformation |
| Feb 21, 2018 | Helena Foulkes reported in an SEC filing no longer being EVP, President-CVS/pharmacy |
| May 10, 2017 | Mary L Schapiro became a director |
| Apr 4, 2017 | Robert O. Kraft reported in an SEC filing no longer being EVP and President - Omnicare |
| Apr 4, 2017 | Jonathan C Roberts listed as EVP & Chief Operating Officer (previously EVP & President, CVS/caremark) in SEC filings |
| Apr 4, 2017 | J. David Joyner reported in an SEC filing no longer being EVP, Sales & Account Services |
| Apr 4, 2017 | Andrew Sussman reported in an SEC filing no longer being EVP & Pres, CVS/minuteclinic |
| Mar 20, 2017 | Eva C Boratto listed as EVP, Cont & Chief Acct Officer (previously SVP, Cont & Chief Acct Officer) in SEC filings |
Not reported recently (20)
- Jean Pierre Millon · Last reported as a director in an SEC filing dated Nov 25, 2024
- Nancy Ann Deparle · Last reported as a director in an SEC filing dated Nov 25, 2024
- Mary L Schapiro · Last reported as a director in an SEC filing dated Nov 25, 2024
- Edward J Ludwig · Last reported as a director in an SEC filing dated May 2, 2024
- Laurie P. Havanec · Last reported as EVP and Chief People Officer in an SEC filing dated Apr 3, 2024
- Sreekanth K Chaguturu · Last reported as EVP and Chief Medical Officer in an SEC filing dated Apr 3, 2024
- Brian A Kane · Last reported as EVP/President, Aetna in an SEC filing dated Apr 3, 2024
- Daniel P Finke · Last reported as EVP/Pres, Health Care Benefits in an SEC filing dated Apr 4, 2023
- Michelle A Peluso · Last reported as EVP and Co-President of Retail in an SEC filing dated Apr 4, 2023
- Thomas M Moriarty · Last reported as EVP & General Counsel in an SEC filing dated Jan 4, 2023
- William C Weldon · Last reported as a director in an SEC filing dated Nov 21, 2022
- Troyen A Brennan · Last reported as EVP and Chief Medical Officer in an SEC filing dated Apr 5, 2022
- Eva C Boratto · Last reported as EVP & CFO in an SEC filing dated May 6, 2021
- Neela Montgomery · Last reported as EVP and Pres., Pharmacy/Retail in an SEC filing dated Apr 2, 2021
- Jonathan E. Mayhew · Last reported as EVP - Transformation in an SEC filing dated Dec 4, 2020
- Richard J Swift · Last reported as a director in an SEC filing dated Nov 22, 2019
- Richard M Bracken · Last reported as a director in an SEC filing dated Nov 22, 2019
- Mark T Bertolini · Last reported as a director in an SEC filing dated Nov 22, 2019
- Kevin Hourican · Last reported as EVP & President, CVS Pharmacy in an SEC filing dated Apr 3, 2019
- Stephen J Gold · Last reported as EVP & CIO in an SEC filing dated Apr 4, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
CVS Proposed Insider Sales (Form 144)
Latest: 2026-05-22
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | AGUIRRE FERNANDO | Director | 2,263 | $214.3K | 2026-05-20 | TD Securities (USA) LLC | — | EDGAR |
| 2026-05-21 | FARAH ROGER N | Director | 2,817 | $263.9K | 2026-05-21 | Charles Schwab Corp. | — | EDGAR |
| 2026-05-08 | TILAK MANDADI | Officer | 69,551 | $6.23M | 2026-05-08 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2025-08-19 | Finucane Anne A. | Director | 7,500 | $532.3K | 2025-08-20 | Merrill Lynch, Pierce, Fenner & … | — | EDGAR |
| 2025-03-05 | Clark James David | Officer | 7,513 | $498.5K | 2025-03-05 | MORGAN STANLEY SMITH BARNEY LLC,… | — | EDGAR |
| 2024-02-16 | PREM S SHAH | Officer | 29,473 | $2.27M | 2024-02-16 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2023-08-03 | Clark James David | Officer | 25,759 | $1.93M | 2023-08-03 | ETRADE FINANCIAL CORPORATION | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-05-18
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Accession | Link |
|---|---|---|
| 2026-05-18 | 0000064803-26-000082 | EDGAR |
| 2026-05-06 | 0000064803-26-000051 | EDGAR |
| 2026-03-19 | 0000064803-26-000017 | EDGAR |
| 2026-02-10 | 0000064803-26-000009 | EDGAR |
| 2025-12-09 | 0000064803-25-000082 | EDGAR |
| 2025-11-20 | 0001193125-25-289805 | EDGAR |
| 2025-10-29 | 0000064803-25-000036 | EDGAR |
| 2025-09-22 | 0001193125-25-211349 | EDGAR |
| 2025-08-15 | 0001193125-25-181862 | EDGAR |
| 2025-07-31 | 0000064803-25-000023 | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-02-10 | 0000064803-26-000010 | EDGAR |
| 2025-02-12 | 0000064803-25-000007 | EDGAR |
| 2024-02-07 | 0000064803-24-000007 | EDGAR |
| 2023-02-08 | 0000064803-23-000009 | EDGAR |
| 2022-02-09 | 0000064803-22-000008 | EDGAR |
| 2021-02-16 | 0000064803-21-000011 | EDGAR |
| 2020-02-18 | 0000064803-20-000007 | EDGAR |
| 2019-02-28 | 0000064803-19-000013 | EDGAR |
| 2018-02-14 | 0001558370-18-000707 | EDGAR |
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-05-06 | 0000064803-26-000052 | EDGAR |
| 2025-10-29 | 0000064803-25-000037 | EDGAR |
| 2025-07-31 | 0000064803-25-000024 | EDGAR |
| 2025-05-01 | 0000064803-25-000013 | EDGAR |
| 2024-11-06 | 0000064803-24-000034 | EDGAR |
| 2024-08-07 | 0000064803-24-000029 | EDGAR |
| 2024-05-01 | 0000064803-24-000016 | EDGAR |
| 2023-11-01 | 0000064803-23-000047 | EDGAR |
| 2023-08-02 | 0000064803-23-000033 | EDGAR |
| 2023-05-03 | 0000064803-23-000016 | EDGAR |
ETF Holders
364 ETFs hold CVS
25 shown · $15.49B total exposure · 0.25% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.15% | $3.5B | — | 2026-09-30 |
| 2 | VOO Vanguard S&P 500 ETF | Vanguard | 0.17% | $2.9B | — | 2026-09-30 |
| 3 | IVV iShares Core S&P 500 ETF | iShares (BlackRock) | 0.18% | $1.6B | $878.4B | 2026-10-21 |
| 4 | SPY State Street® SPDR® S&P 500® ETF Trust | SPDR (State Street) | 0.18% | $1.5B | $820.7B | 2026-10-21 |
| 5 | VTV Vanguard Morningstar Value ETF | Vanguard | 0.42% | $1.0B | — | 2026-09-30 |
| 6 | XLV State Street® Health Care Select Sector SPDR® ETF | SPDR (State Street) | 1.83% | $867.4M | $47.5B | 2026-10-21 |
| 7 | VYM Vanguard High Dividend Yield ETF | Vanguard | 0.47% | $447.4M | — | 2026-09-30 |
| 8 | COWZ Pacer US Cash Cows 100 ETF | Nport | 2.16% | $392.0M | — | 2026-04-30 |
| 9 | VHT Vanguard Health Care ETF | Vanguard | 1.53% | $334.1M | — | 2026-09-30 |
| 10 | SPYM State Street® SPDR® Portfolio S&P 500® ETF | SPDR (State Street) | 0.18% | $327.3M | $184.5B | 2026-10-21 |
| 11 | DVY iShares Select Dividend ETF | iShares (BlackRock) | 1.36% | $316.9M | $23.7B | 2026-10-21 |
| 12 | IWD iShares Russell 1000 Value ETF | iShares (BlackRock) | 0.32% | $268.2M | $84.8B | 2026-10-21 |
| 13 | FNDX Schwab Fundamental U.S. Large Company ETF | Nport | 0.91% | $232.3M | — | 2026-05-31 |
| 14 | RWL Invesco S&P 500 Revenue ETF | Invesco | 2.00% | $206.3M | — | 2026-10-21 |
| 15 | IVE iShares S&P 500 Value ETF | iShares (BlackRock) | 0.39% | $198.7M | $50.7B | 2026-10-21 |
| 16 | RSP Invesco S&P 500 Equal Weight ETF | Invesco | 0.19% | $192.3M | — | 2026-10-21 |
| 17 | IHF iShares U.S. Healthcare Providers ETF | iShares (BlackRock) | 12.23% | $169.0M | $1.4B | 2026-10-21 |
| 18 | SPMO Invesco S&P 500 Momentum ETF | Invesco | 0.72% | $160.0M | — | 2026-10-21 |
| 19 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.16% | $155.3M | $96.2B | 2026-10-21 |
| 20 | SPYV State Street® SPDR® Portfolio S&P 500® Value ETF | SPDR (State Street) | 0.39% | $150.5M | $38.4B | 2026-10-21 |
| 21 | MTUM iShares MSCI USA Momentum Factor ETF | iShares (BlackRock) | 0.74% | $138.9M | $18.1B | 2026-10-21 |
| 22 | VV Vanguard Morningstar Large-Cap ETF | Vanguard | 0.17% | $129.1M | — | 2026-09-30 |
| 23 | VLUE iShares MSCI USA Value Factor ETF | iShares (BlackRock) | 1.36% | $125.3M | $9.2B | 2026-10-21 |
| 24 | SCHX Schwab U.S. Large-Cap ETF | Nport | 0.17% | $123.0M | — | 2026-05-31 |
| 25 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.13% | $111.0M | — | 2026-10-21 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
24.86
TTM Diluted EPS
$3.80
TTM Revenue
$412.64B
TTM Net Income
$4.89B
TTM Op. Cash Flow
$14.78B
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $105.45B | $2.98B | $2.31 | $6.34B |
| Q1 '26 | 2026-03-31 | $99.85B | $2.94B | $2.30 | $4.25B |
| Q4 '25 | 2025-12-31 | $105.10B | $2.94B | $2.32 | $3.39B |
| Q3 '25 | 2025-09-30 | $102.24B | $-3.98B | $-3.13 | $796.00M |
| Q2 '25 | 2025-06-30 | $98.43B | $1.02B | $0.80 | $1.90B |
| Q1 '25 | 2025-03-31 | $94.07B | $1.78B | $1.41 | $4.56B |
| Q4 '24 | 2024-12-31 | $96.95B | $1.64B | $1.31 | $1.86B |
| Q3 '24 | 2024-09-30 | $94.88B | $87.00M | $0.07 | $-745.00M |
| Q2 '24 | 2024-06-30 | $90.84B | $1.77B | $1.41 | $3.09B |
| Q1 '24 | 2024-03-31 | $87.98B | $1.11B | $0.88 | $4.90B |
| Q4 '23 | 2023-12-31 | $93.55B | $2.05B | $1.59 | $-2.64B |
| Q3 '23 | 2023-09-30 | $89.49B | $2.26B | $1.75 | $2.72B |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-05
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
24.86
P/B
1.51
P/S
0.29
EV/EBITDA
10.48
EV/Sales
0.41
ROE
6.1%
ROA
1.9%
Div Yield
2.86%
FCF Yield
12.26%
Debt/Equity
0.74
Current Ratio
—
Market Cap
$120.60B
as of 2026-10-22
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
16.47M
SI % of Float
1.30%
Days to Cover
1.66
Short Vol Ratio
46.5%
Free Float
1.27B
Float %
99.3%
Short interest 2026-09-30 • Short volume 2026-10-22 • Float 2026-08-24